Clinical breast cancer最新文献_第4页

Omission of Axillary Lymph Node Dissection in Early-Stage Breast Cancer With Limited Sentinel Lymph Node Metastasis: A Propensity Score-Matched Analysis. 有局限性前哨淋巴结转移的早期乳腺癌遗漏腋窝淋巴结清扫：倾向评分匹配分析。

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-09 DOI: 10.1016/j.clbc.2025.12.006

Changzai Li, Pan Zhang, Jiaxing Wang, Cuizhi Geng

Background: Whether axillary lymph node dissection (ALND) can be safely omitted clinically node-negative (cN0) breast cancer with limited sentinel lymph (SLN) metastasis remains uncertain, particularly after mastectomy.

Methods: This retrospective cohort included women with T1-T2 cN0 breast cancer and positive SLN between 2015 and 2020. Patents underwent sentinel lymph node biopsy (SLNB) alone or ALND. Propensity score matching (1:1, nearest neighbor, caliper 0.02 on logit) balanced age, T stage, tumor grade, vascular invasion, number of positive SLNs, ER/PR/HER2, Ki-67, surgery type, chemotherapy, and radiotherapy. Kaplan-Meier and Cox regression estimated overall survival (OS) recurrence-free survival (RFS).

Results: Of 1244 patients screened, 1038 were analyzed (577 ALND, 461 SLNB alone; median follow-up 68 months), After matching (283 pairs), 5-year OS was 97.1% (95% CI, 95.0-99.3) for ALND and 96.1% (93.8-98.5) for SLNB alone. Five-year RFS was 96.8% (94.7-99.0) versus 97.0% (94.9-99.0). No statistically significant difference was found in OS (HR, 1.14, 95% CI, 0.51-2.54, P = .75) and RFS (HR, 0.86, 95% CI, 0.36-2.05, P = .74) between the ALND and SLNB alone. Findings were consistent among patients with 1 to 3 positive SLNs, regardless of surgery type. All 22 patients with 4 to 6 positive SLNs underwent ALND, precluding comparison.

Conclusion: In cN0 breast cancer patients with 1 to 3 positive SLNs, omitting ALND did not compromise OS or RFS after mastectomy or breast-conserving surgery. These results support broader application of de-escalated axillary surgery while prospective validation for higher nodal burden remains necessary.

背景：临床上淋巴结阴性（cN0）伴有有限前哨淋巴结（SLN）转移的乳腺癌是否可以安全地省略腋窝淋巴结清扫（ALND）仍不确定，特别是在乳房切除术后。方法：该回顾性队列包括2015年至2020年间患有T1-T2 cN0乳腺癌和SLN阳性的女性。患者接受单独前哨淋巴结活检（SLNB）或ALND。倾向评分匹配（1:1，最近邻，卡尺在logit上为0.02）平衡年龄，T分期，肿瘤分级，血管侵犯，阳性sln数量，ER/PR/HER2, Ki-67，手术类型，化疗和放疗。Kaplan-Meier和Cox回归估计总生存期（OS）和无复发生存期（RFS）。结果：在筛选的1244例患者中，分析了1038例（577例ALND， 461例单用SLNB，中位随访68个月），匹配后（283对），ALND的5年OS为97.1% (95% CI, 95.0-99.3)，单用SLNB的5年OS为96.1%（93.8-98.5）。5年RFS分别为96.8%（94.7-99.0）和97.0%（94.9-99.0）。在OS （HR, 1.14, 95% CI, 0.51-2.54, P = 0.75）和RFS （HR, 0.86, 95% CI, 0.36-2.05, P = 0.74）方面，ALND与SLNB两组比较无统计学差异。无论手术类型如何，1 - 3例sln阳性患者的结果是一致的。所有22例4 - 6例sln阳性患者均行ALND，排除了比较。结论：在1 ~ 3例sln阳性的cN0乳腺癌患者中，省略ALND并不影响乳房切除术或保乳手术后的OS或RFS。这些结果支持腋窝降压手术的广泛应用，但对于更高淋巴结负担的前瞻性验证仍然是必要的。

{"title":"Omission of Axillary Lymph Node Dissection in Early-Stage Breast Cancer With Limited Sentinel Lymph Node Metastasis: A Propensity Score-Matched Analysis.","authors":"Changzai Li, Pan Zhang, Jiaxing Wang, Cuizhi Geng","doi":"10.1016/j.clbc.2025.12.006","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.12.006","url":null,"abstract":"<p><strong>Background: </strong>Whether axillary lymph node dissection (ALND) can be safely omitted clinically node-negative (cN0) breast cancer with limited sentinel lymph (SLN) metastasis remains uncertain, particularly after mastectomy.</p><p><strong>Methods: </strong>This retrospective cohort included women with T1-T2 cN0 breast cancer and positive SLN between 2015 and 2020. Patents underwent sentinel lymph node biopsy (SLNB) alone or ALND. Propensity score matching (1:1, nearest neighbor, caliper 0.02 on logit) balanced age, T stage, tumor grade, vascular invasion, number of positive SLNs, ER/PR/HER2, Ki-67, surgery type, chemotherapy, and radiotherapy. Kaplan-Meier and Cox regression estimated overall survival (OS) recurrence-free survival (RFS).</p><p><strong>Results: </strong>Of 1244 patients screened, 1038 were analyzed (577 ALND, 461 SLNB alone; median follow-up 68 months), After matching (283 pairs), 5-year OS was 97.1% (95% CI, 95.0-99.3) for ALND and 96.1% (93.8-98.5) for SLNB alone. Five-year RFS was 96.8% (94.7-99.0) versus 97.0% (94.9-99.0). No statistically significant difference was found in OS (HR, 1.14, 95% CI, 0.51-2.54, P = .75) and RFS (HR, 0.86, 95% CI, 0.36-2.05, P = .74) between the ALND and SLNB alone. Findings were consistent among patients with 1 to 3 positive SLNs, regardless of surgery type. All 22 patients with 4 to 6 positive SLNs underwent ALND, precluding comparison.</p><p><strong>Conclusion: </strong>In cN0 breast cancer patients with 1 to 3 positive SLNs, omitting ALND did not compromise OS or RFS after mastectomy or breast-conserving surgery. These results support broader application of de-escalated axillary surgery while prospective validation for higher nodal burden remains necessary.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in Survival and Associated Characteristics Between Asian American and White Patients With Breast Cancer 亚裔美国人和白人乳腺癌患者的生存和相关特征的差异

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-06 DOI: 10.1016/j.clbc.2026.01.001

Yongxin Li , Dexiang Li , Xinlong Tao , Yinyin Ye , Xiao Liang , Xingchang Qiu , Junjie Ma , Zhibo Liu , Jiuda Zhao

Background

Extensive research has explored racial differences in breast cancer survival, particularly between Black and White patients. However, few studies have included comparisons with Asian American and White populations.

Methods

We conducted a retrospective cohort study using data from the SEER database (2010-2021) for Asian American and White patients with breast cancer. Propensity score matching (PSM) was applied to balance baseline characteristics including age, stage, molecular subtype, and treatment. Survival analyses included Kaplan–Meier (KM) curves, Cox proportional hazards models, and subgroup analyses. Outcomes were overall survival (OS) and breast cancer-specific survival (BCSS).

Results

This study included 374,930 patients with breast cancer, with 44,092 Asian American patients with breast cancer and 330,838 White patients with breast cancer. After PSM balanced baseline characteristics, Asian American patients with breast cancer showed significantly better OS (HR = 0.78, 95% CI, 0.75-0.81) and BCSS (HR = 0.88, 95% CI, 0.84-0.93) than White patients with breast cancer. Consistent survival advantages were observed across all clinical and demographic subgroups. After adjustment for key prognostic factors including stage, age, and treatment, Asian American patients with breast cancer remained independently associated with significantly improved survival (OS, HR = 0.77; BCSS, HR = 0.86).

Conclusions

Asian American patients with breast cancer demonstrated significantly better survival than White patients with breast cancer after adjusting for multiple factors, with a consistent advantage across subgroups. This suggests intrinsic biological or lifestyle protective factors, warranting further investigation.

广泛的研究探讨了乳腺癌生存的种族差异，特别是黑人和白人患者之间的差异。然而，很少有研究将亚裔美国人和白人进行比较。方法：我们使用来自SEER数据库（2010-2021）的数据，对亚裔美国人和白人乳腺癌患者进行回顾性队列研究。倾向评分匹配（PSM）用于平衡基线特征，包括年龄、分期、分子亚型和治疗。生存分析包括Kaplan-Meier （KM）曲线、Cox比例风险模型和亚组分析。结果是总生存（OS）和乳腺癌特异性生存（BCSS）。结果本研究纳入374,930例乳腺癌患者，其中44,092例亚裔乳腺癌患者和330,838例白人乳腺癌患者。在PSM平衡基线特征后，亚裔美国乳腺癌患者的OS （HR = 0.78, 95% CI, 0.75-0.81）和BCSS （HR = 0.88, 95% CI, 0.84-0.93）明显优于白人乳腺癌患者。在所有临床和人口统计学亚组中观察到一致的生存优势。在调整了包括分期、年龄和治疗在内的关键预后因素后，亚裔美国人乳腺癌患者仍然与显著改善的生存率独立相关（OS, HR = 0.77； BCSS, HR = 0.86）。结论经多种因素调整后，亚裔美国乳腺癌患者的生存率明显高于白人乳腺癌患者，且在亚组间具有一致的优势。这表明内在的生物或生活方式保护因素，值得进一步研究。

{"title":"Differences in Survival and Associated Characteristics Between Asian American and White Patients With Breast Cancer","authors":"Yongxin Li , Dexiang Li , Xinlong Tao , Yinyin Ye , Xiao Liang , Xingchang Qiu , Junjie Ma , Zhibo Liu , Jiuda Zhao","doi":"10.1016/j.clbc.2026.01.001","DOIUrl":"10.1016/j.clbc.2026.01.001","url":null,"abstract":"<div><h3>Background</h3><div>Extensive research has explored racial differences in breast cancer survival, particularly between Black and White patients. However, few studies have included comparisons with Asian American and White populations.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using data from the SEER database (2010-2021) for Asian American and White patients with breast cancer. Propensity score matching (PSM) was applied to balance baseline characteristics including age, stage, molecular subtype, and treatment. Survival analyses included Kaplan–Meier (KM) curves, Cox proportional hazards models, and subgroup analyses. Outcomes were overall survival (OS) and breast cancer-specific survival (BCSS).</div></div><div><h3>Results</h3><div>This study included 374,930 patients with breast cancer, with 44,092 Asian American patients with breast cancer and 330,838 White patients with breast cancer. After PSM balanced baseline characteristics, Asian American patients with breast cancer showed significantly better OS (HR = 0.78, 95% CI, 0.75-0.81) and BCSS (HR = 0.88, 95% CI, 0.84-0.93) than White patients with breast cancer. Consistent survival advantages were observed across all clinical and demographic subgroups. After adjustment for key prognostic factors including stage, age, and treatment, Asian American patients with breast cancer remained independently associated with significantly improved survival (OS, HR = 0.77; BCSS, HR = 0.86).</div></div><div><h3>Conclusions</h3><div>Asian American patients with breast cancer demonstrated significantly better survival than White patients with breast cancer after adjusting for multiple factors, with a consistent advantage across subgroups. This suggests intrinsic biological or lifestyle protective factors, warranting further investigation.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 1-8"},"PeriodicalIF":2.5,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Lobular Histology a Predictor of Sentinel Node Positivity in Early Breast Cancer? An Integrated Analysis of Histological Subtype and Preoperative Imaging 小叶组织学是早期乳腺癌前哨淋巴结阳性的预测指标吗？组织学亚型与术前影像学的综合分析。

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-06 DOI: 10.1016/j.clbc.2026.01.002

Francesca Accomasso , Gaia Ruggeri , Silvia Actis , Elena Paradiso , Pier Giorgio Spanu , Luca Giuseppe Sgro , Annamaria Ferrero , Valentina Elisabetta Bounous

Purpose

To assess whether lobular histology independently predicts sentinel lymph node biopsy (SLNB) positivity in early-stage clinically node-negative (cN0) breast cancer (BC), to identify other predictive factors of SLNB positivity, and to evaluate the diagnostic performance of preoperative axillary imaging. The cumulative incidence of local and distant recurrences were also evaluated.

Methods

We retrospectively analyzed 661 patients with early-stage, cN0 BC undergoing surgery with SLNB. Clinical, pathological, and radiological data were assessed. Univariate and multivariate analyses were performed to identify predictors of SLNB positivity. The cumulative incidence of axillary and distant recurrences were calculated including only patients with at least 2 years follow up, for a total of 495 patients.

Results

ILC was present in 16.9% of cases. SLNB positivity occurred in 16.1% of invasive lobular cancers (ILC) and 20% of nonspecial type tumors (NST) (P = .3). No significant differences in axillary lymph node dissection (ALND) rates or nodal upstaging were found between histologies. Tumor size > 20 mm and vascular invasion were independent predictors of SLNB positivity. Axillary ultrasound and magnetic resonance (MRI) showed high specificity (95% and 79%) and negative predictive value (80% and 98%) in identifying node-negative patients. No axillary recurrences occurred after a median follow-up of 49.3 months.

Conclusions

ILC does not independently predict SLNB positivity or nodal upstaging. Tumor size and vascular invasion remain the strongest predictors. Axillary ultrasound and MRI are reliable tools to guide de-escalation. SLNB omission in well-selected cN0 patients, including those with ILC, may be considered in tailored and selected patients.

目的：评估小叶组织学是否能独立预测早期临床淋巴结阴性（cN0）乳腺癌前哨淋巴结活检（SLNB）阳性，确定SLNB阳性的其他预测因素，并评价术前腋窝影像学的诊断价值。局部和远处复发的累积发生率也进行了评估。方法：我们回顾性分析了661例接受SLNB手术的早期cN0 BC患者。评估临床、病理和放射学资料。进行单因素和多因素分析以确定SLNB阳性的预测因素。计算腋窝和远处复发的累积发生率，仅包括随访至少2年的患者，共495例患者。结果：16.9%的病例存在ILC。浸润性小叶癌（ILC）和非特殊型肿瘤（NST）的SLNB阳性率分别为16.1%和20% （P = 0.3）。腋窝淋巴结清扫（ALND）率和淋巴结分期差异无统计学意义。肿瘤大小bbb20 mm和血管浸润是SLNB阳性的独立预测因子。腋窝超声和磁共振（MRI）在识别淋巴结阴性患者方面具有高特异性（95%和79%）和阴性预测值（80%和98%）。中位随访49.3个月，无腋窝复发。结论：ILC不能独立预测SLNB阳性或淋巴结抢先。肿瘤大小和血管浸润仍然是最强的预测因子。腋窝超声和MRI是指导降级的可靠工具。在精心挑选的cN0患者中，包括那些患有ILC的患者，可以考虑在精心挑选的患者中遗漏SLNB。

{"title":"Is Lobular Histology a Predictor of Sentinel Node Positivity in Early Breast Cancer? An Integrated Analysis of Histological Subtype and Preoperative Imaging","authors":"Francesca Accomasso , Gaia Ruggeri , Silvia Actis , Elena Paradiso , Pier Giorgio Spanu , Luca Giuseppe Sgro , Annamaria Ferrero , Valentina Elisabetta Bounous","doi":"10.1016/j.clbc.2026.01.002","DOIUrl":"10.1016/j.clbc.2026.01.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess whether lobular histology independently predicts sentinel lymph node biopsy (SLNB) positivity in early-stage clinically node-negative (cN0) breast cancer (BC), to identify other predictive factors of SLNB positivity, and to evaluate the diagnostic performance of preoperative axillary imaging. The cumulative incidence of local and distant recurrences were also evaluated.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 661 patients with early-stage, cN0 BC undergoing surgery with SLNB. Clinical, pathological, and radiological data were assessed. Univariate and multivariate analyses were performed to identify predictors of SLNB positivity. The cumulative incidence of axillary and distant recurrences were calculated including only patients with at least 2 years follow up, for a total of 495 patients.</div></div><div><h3>Results</h3><div>ILC was present in 16.9% of cases. SLNB positivity occurred in 16.1% of invasive lobular cancers (ILC) and 20% of nonspecial type tumors (NST) (<em>P</em> = .3). No significant differences in axillary lymph node dissection (ALND) rates or nodal upstaging were found between histologies. Tumor size > 20 mm and vascular invasion were independent predictors of SLNB positivity. Axillary ultrasound and magnetic resonance (MRI) showed high specificity (95% and 79%) and negative predictive value (80% and 98%) in identifying node-negative patients. No axillary recurrences occurred after a median follow-up of 49.3 months.</div></div><div><h3>Conclusions</h3><div>ILC does not independently predict SLNB positivity or nodal upstaging. Tumor size and vascular invasion remain the strongest predictors. Axillary ultrasound and MRI are reliable tools to guide de-escalation. SLNB omission in well-selected cN0 patients, including those with ILC, may be considered in tailored and selected patients.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 9-16"},"PeriodicalIF":2.5,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LINC00511 Promotes Breast Cancer Cell Proliferation and Invasion by Mediating MYC-Mediated Regulation of VASP. LINC00511通过介导myc介导的VASP调控促进乳腺癌细胞增殖和侵袭。

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-05 DOI: 10.1016/j.clbc.2025.12.010

Sirui Huang, Yiqing Xi, Jingbo Gao, Shilong Yu, Le Chen, Yuxia Duan, Zelin Yang, Yu Peng, Lei Wei, Jingwei Zhang

Background: Breast cancer remains a significant health issue, with a persistent annual increase in incidence rates and high mortality. MYC, a critical transcription factor, is often dysregulated in breast cancer, driving tumor progression. Long noncoding RNAs (lncRNAs) have emerged as key regulators in cancer, influencing gene expression through various mechanisms. This study investigates the role of lncRNAs in mediating MYC function and their impact on breast cancer progression.

Methods: We analyzed 1212 breast cancer samples from The Cancer Genome Atlas (TCGA) database to identify lncRNAs related to MYC targets. The expression levels of lncRNAs were correlated with MYC-TARGET scores to develop a prognostic model. Functional studies were performed on LINC00511, a key lncRNA identified in the model, to elucidate its role in breast cancer progression. RNA Immunoprecipitation (RIP), Chromatin Immunoprecipitation (ChIP) and Dual-Luciferase Reporter Gene Assay assays were used to validate interactions between LINC00511, MYC, and the target gene VASP (vasodilator-stimulated phosphoprotein).

Results: MYC-TARGET scores were significantly correlated with poor prognosis in breast cancer patients. We identified 38 lncRNAs associated with MYC targets, and LINC00511 was selected for further analysis due to its high expression and correlation with poor prognosis. A prognostic model composed of 5 lncRNAs (including LINC00511) was developed, with a risk score that independently predicted patient outcomes . Functional experiments showed that LINC00511 promoted breast cancer cell proliferation, migration, and invasion. Mechanistically, LINC00511 interacted with MYC to upregulate VASP expression. VASP knockdown significantly reduced breast cancer cell proliferation and migration. Overexpression of MYC rescued the inhibitory effects of LINC00511 knockdown on VASP expression and cell invasion/migration.

Conclusions: LINC00511 promotes breast cancer progression by mediating MYC to regulate VASP expression. This study highlights the importance of lncRNAs in cancer transcriptional networks and identifies LINC00511 as a potential therapeutic target for breast cancer.

背景：乳腺癌仍然是一个重大的健康问题，其发病率和死亡率每年都在持续增加。MYC是一种关键的转录因子，在乳腺癌中经常失调，驱动肿瘤进展。长链非编码rna （lncRNAs）已成为癌症的关键调控因子，通过多种机制影响基因表达。本研究探讨了lncrna在介导MYC功能中的作用及其对乳腺癌进展的影响。方法：我们分析了来自癌症基因组图谱（TCGA）数据库的1212例乳腺癌样本，以鉴定与MYC靶点相关的lncrna。lncrna的表达水平与MYC-TARGET评分相关，以建立预后模型。我们对该模型中发现的关键lncRNA LINC00511进行了功能研究，以阐明其在乳腺癌进展中的作用。采用RNA免疫沉淀（RIP）、染色质免疫沉淀（ChIP）和双荧光素酶报告基因测定（Dual-Luciferase Reporter Gene Assay）验证LINC00511、MYC和靶基因VASP（血管扩张剂刺激磷酸化蛋白）之间的相互作用。结果：乳腺癌患者MYC-TARGET评分与预后不良有显著相关性。我们确定了38个与MYC靶点相关的lncrna，由于其高表达和与不良预后相关，我们选择了LINC00511进行进一步分析。建立了一个由5个lncrna（包括LINC00511）组成的预后模型，其风险评分可独立预测患者预后。功能实验表明，LINC00511促进乳腺癌细胞增殖、迁移和侵袭。机制上，LINC00511与MYC相互作用上调VASP的表达。VASP敲低可显著降低乳腺癌细胞的增殖和迁移。MYC过表达恢复了LINC00511敲低对VASP表达和细胞侵袭/迁移的抑制作用。结论：LINC00511通过介导MYC调控VASP表达促进乳腺癌进展。本研究强调了lncrna在癌症转录网络中的重要性，并确定了LINC00511作为乳腺癌的潜在治疗靶点。

{"title":"LINC00511 Promotes Breast Cancer Cell Proliferation and Invasion by Mediating MYC-Mediated Regulation of VASP.","authors":"Sirui Huang, Yiqing Xi, Jingbo Gao, Shilong Yu, Le Chen, Yuxia Duan, Zelin Yang, Yu Peng, Lei Wei, Jingwei Zhang","doi":"10.1016/j.clbc.2025.12.010","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.12.010","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a significant health issue, with a persistent annual increase in incidence rates and high mortality. MYC, a critical transcription factor, is often dysregulated in breast cancer, driving tumor progression. Long noncoding RNAs (lncRNAs) have emerged as key regulators in cancer, influencing gene expression through various mechanisms. This study investigates the role of lncRNAs in mediating MYC function and their impact on breast cancer progression.</p><p><strong>Methods: </strong>We analyzed 1212 breast cancer samples from The Cancer Genome Atlas (TCGA) database to identify lncRNAs related to MYC targets. The expression levels of lncRNAs were correlated with MYC-TARGET scores to develop a prognostic model. Functional studies were performed on LINC00511, a key lncRNA identified in the model, to elucidate its role in breast cancer progression. RNA Immunoprecipitation (RIP), Chromatin Immunoprecipitation (ChIP) and Dual-Luciferase Reporter Gene Assay assays were used to validate interactions between LINC00511, MYC, and the target gene VASP (vasodilator-stimulated phosphoprotein).</p><p><strong>Results: </strong>MYC-TARGET scores were significantly correlated with poor prognosis in breast cancer patients. We identified 38 lncRNAs associated with MYC targets, and LINC00511 was selected for further analysis due to its high expression and correlation with poor prognosis. A prognostic model composed of 5 lncRNAs (including LINC00511) was developed, with a risk score that independently predicted patient outcomes . Functional experiments showed that LINC00511 promoted breast cancer cell proliferation, migration, and invasion. Mechanistically, LINC00511 interacted with MYC to upregulate VASP expression. VASP knockdown significantly reduced breast cancer cell proliferation and migration. Overexpression of MYC rescued the inhibitory effects of LINC00511 knockdown on VASP expression and cell invasion/migration.</p><p><strong>Conclusions: </strong>LINC00511 promotes breast cancer progression by mediating MYC to regulate VASP expression. This study highlights the importance of lncRNAs in cancer transcriptional networks and identifies LINC00511 as a potential therapeutic target for breast cancer.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical Considerations for the Use of Antiemetics in Pregnant Patients With Breast Cancer 妊娠乳腺癌患者使用止吐药的实际考虑

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-03 DOI: 10.1016/j.clbc.2025.12.012

Arianne Duong , Dane Fritzsche , Amy Ly Indorf

Early breast cancer treatment commonly includes highly emetogenic chemotherapy and immunotherapy regimens. Both pregnancy and chemotherapy treatment are associated with nausea and vomiting, and many agents used to treat pregnancy-associated nausea have limited data for CINV. Guidelines recommend a 4-drug antiemetic regimen for highly emetogenic chemotherapy regimens. Designing antiemetic regimens for pregnant women undergoing treatment for early breast cancer remains a challenge because of a lack of safety data for commonly used antiemetics as well as physiologic changes that occur throughout pregnancy This review aims to discuss current literature and guideline recommendations and provide practical considerations for agents used in chemotherapy-induced nausea and vomiting prevention in pregnant patients with breast cancer. A literature search on nausea pathophysiology, treatment of pregnant breast cancer patients, antiemetic use in pregnancy and chemotherapy-induced nausea and vomiting was conducted. Primary and tertiary literature sources were reviewed and cited. An overview of nausea pathophysiology and general treatment principles of treatment and supportive care in pregnant breast cancer patients is outlined. Five major antiemetic drug classes are reviewed in this article. When designing antiemetic regimens for pregnant patients undergoing chemotherapy treatment, clinicians must consider the current evidence, including safety, side effects, and pharmacokinetics of various agents, as well as pregnancy trimester and associated physiologic changes. Optimal management and prevention of chemotherapy-induced nausea and vomiting is crucial to avoid treatment delays and hospitalization, and to maximize patient quality of life.

早期乳腺癌治疗通常包括高致吐性化疗和免疫治疗方案。妊娠和化疗都与恶心和呕吐有关，许多用于治疗妊娠相关恶心的药物对CINV的数据有限。指南建议高度致吐性化疗方案采用4药止吐方案。为接受早期乳腺癌治疗的孕妇设计止吐方案仍然是一个挑战，因为缺乏常用止吐药的安全性数据以及妊娠期间发生的生理变化。本综述旨在讨论目前的文献和指南建议，并为用于预防化疗引起的妊娠乳腺癌患者恶心和呕吐的药物提供实际考虑。对恶心病理生理、妊娠期乳腺癌患者的治疗、妊娠期止吐药的使用及化疗引起的恶心呕吐进行文献检索。回顾和引用了一级和三级文献来源。概述恶心病理生理和一般治疗原则的治疗和支持护理怀孕乳腺癌患者概述。本文综述了五种主要的止吐药物。在为接受化疗的孕妇设计止吐方案时，临床医生必须考虑现有的证据，包括安全性、副作用、各种药物的药代动力学，以及妊娠期和相关的生理变化。最佳管理和预防化疗引起的恶心和呕吐对于避免治疗延误和住院治疗以及最大限度地提高患者的生活质量至关重要。

{"title":"Practical Considerations for the Use of Antiemetics in Pregnant Patients With Breast Cancer","authors":"Arianne Duong , Dane Fritzsche , Amy Ly Indorf","doi":"10.1016/j.clbc.2025.12.012","DOIUrl":"10.1016/j.clbc.2025.12.012","url":null,"abstract":"<div><div>Early breast cancer treatment commonly includes highly emetogenic chemotherapy and immunotherapy regimens. Both pregnancy and chemotherapy treatment are associated with nausea and vomiting, and many agents used to treat pregnancy-associated nausea have limited data for CINV. Guidelines recommend a 4-drug antiemetic regimen for highly emetogenic chemotherapy regimens. Designing antiemetic regimens for pregnant women undergoing treatment for early breast cancer remains a challenge because of a lack of safety data for commonly used antiemetics as well as physiologic changes that occur throughout pregnancy This review aims to discuss current literature and guideline recommendations and provide practical considerations for agents used in chemotherapy-induced nausea and vomiting prevention in pregnant patients with breast cancer. A literature search on nausea pathophysiology, treatment of pregnant breast cancer patients, antiemetic use in pregnancy and chemotherapy-induced nausea and vomiting was conducted. Primary and tertiary literature sources were reviewed and cited. An overview of nausea pathophysiology and general treatment principles of treatment and supportive care in pregnant breast cancer patients is outlined. Five major antiemetic drug classes are reviewed in this article. When designing antiemetic regimens for pregnant patients undergoing chemotherapy treatment, clinicians must consider the current evidence, including safety, side effects, and pharmacokinetics of various agents, as well as pregnancy trimester and associated physiologic changes. Optimal management and prevention of chemotherapy-induced nausea and vomiting is crucial to avoid treatment delays and hospitalization, and to maximize patient quality of life.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 2","pages":"Pages 80-86"},"PeriodicalIF":2.5,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Residual Axillary Lymph Node Metastases After Neoadjuvant Treatment in Breast Cancer 乳腺癌新辅助治疗后残留腋窝淋巴结转移的评价。

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-01 DOI: 10.1016/j.clbc.2025.07.011

Rodrigo Vaz Reis , Paula Pinto , Bárbara Peleteiro , José Luís Fougo

Background

The present study aims to evaluate the volume of residual axillary nodal disease after neoadjuvant chemotherapy (NACT) in breast cancer.

Methods

Predictive factors for low-volume residual axillary nodal disease were analyzed in patients with histologically proven breast cancer (cT1-3 cN0-2) who were treated with NACT and surgery between 2015 and 2019.

Results

A total of 734 patients were analyzed. Breast pathological complete response (pCR) was achieved in 35.1%, with 31.5% showing no residual tumor in the breast or axillary lymph nodes (LNs). Breast and axillary pCR rates varied according to receptor subtype, with the highest rates found in HER2+ and hormone receptor (HR) negative tumors. Among 385 patients presenting with axillary metastases at diagnosis, 41.0% achieved axillary pCR, and 38.4% had 1–3 metastatic LNs. Predictive factors for axillary pCR included cN stage, HR status, ycN status, and breast pCR. For breast pCR patients with cN+ at presentation, the rate of axillary pCR was 81.1%. After NACT, 68.7% of patients with >2 metastatic LNs at diagnosis had 0-3 residual LNs.

Conclusion

We conclude that breast pCR, HER2+, HR negative breast cancer, <3 metastatic axillary LNs at diagnosis, and complete axillary imaging response after NACT were associated with axillary pCR rates and low probability of >3 positive LNs. Similarly, our study showed that axillary pCR in patients with more than 2 metastatic LNs was comparable to that of patients with 1-2 metastatic LNs highlighting an opportunity to tailor axillary surgery in this subgroup.

背景：本研究旨在评估乳腺癌新辅助化疗（NACT）后残留腋窝淋巴结的体积。方法：分析2015年至2019年期间经组织学证实的乳腺癌（cT1-3 cN0-2）接受NACT和手术治疗的小体积残留腋窝淋巴结病的预测因素。结果：共分析734例患者。35.1%的患者达到乳腺病理完全缓解（pCR）， 31.5%的患者乳腺或腋窝淋巴结（LNs）无残留肿瘤。乳腺和腋窝的pCR率因受体亚型而异，HER2+和激素受体（HR）阴性肿瘤的pCR率最高。在诊断时出现腋窝转移的385例患者中，41.0%的患者实现了腋窝pCR， 38.4%的患者有1-3个转移灶。腋窝pCR的预测因素包括cN分期、HR状态、ycN状态和乳腺pCR。在出现cN+的乳腺pCR患者中，腋窝pCR的检出率为81.1%。经NACT治疗后，68.7%诊断为bbbb2转移性LNs的患者有0-3个残留LNs。结论：乳腺癌pCR， HER2+， HR阴性乳腺癌，3个阳性LNs。同样，我们的研究表明，2个以上转移性LNs患者的腋窝pCR与1-2个转移性LNs患者的腋窝pCR相当，这表明该亚组有机会进行量身定制的腋窝手术。

{"title":"Evaluation of Residual Axillary Lymph Node Metastases After Neoadjuvant Treatment in Breast Cancer","authors":"Rodrigo Vaz Reis , Paula Pinto , Bárbara Peleteiro , José Luís Fougo","doi":"10.1016/j.clbc.2025.07.011","DOIUrl":"10.1016/j.clbc.2025.07.011","url":null,"abstract":"<div><h3>Background</h3><div>The present study aims to evaluate the volume of residual axillary nodal disease after neoadjuvant chemotherapy (NACT) in breast cancer.</div></div><div><h3>Methods</h3><div>Predictive factors for low-volume residual axillary nodal disease were analyzed in patients with histologically proven breast cancer (cT1-3 cN0-2) who were treated with NACT and surgery between 2015 and 2019.</div></div><div><h3>Results</h3><div>A total of 734 patients were analyzed. Breast pathological complete response (pCR) was achieved in 35.1%, with 31.5% showing no residual tumor in the breast or axillary lymph nodes (LNs). Breast and axillary pCR rates varied according to receptor subtype, with the highest rates found in HER2+ and hormone receptor (HR) negative tumors. Among 385 patients presenting with axillary metastases at diagnosis, 41.0% achieved axillary pCR, and 38.4% had 1–3 metastatic LNs. Predictive factors for axillary pCR included cN stage, HR status, ycN status, and breast pCR. For breast pCR patients with cN+ at presentation, the rate of axillary pCR was 81.1%. After NACT, 68.7% of patients with >2 metastatic LNs at diagnosis had 0-3 residual LNs.</div></div><div><h3>Conclusion</h3><div>We conclude that breast pCR, HER2+, HR negative breast cancer, <3 metastatic axillary LNs at diagnosis, and complete axillary imaging response after NACT were associated with axillary pCR rates and low probability of >3 positive LNs. Similarly, our study showed that axillary pCR in patients with more than 2 metastatic LNs was comparable to that of patients with 1-2 metastatic LNs highlighting an opportunity to tailor axillary surgery in this subgroup.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 195-203"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Resistance Training at Different Intensities on Preventing Breast Cancer-Related Lymphedema: A 1-Year Randomized Controlled Trial 不同强度的阻力训练对预防乳腺癌相关淋巴水肿的影响：一项为期1年的随机对照试验

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-01 DOI: 10.1016/j.clbc.2025.07.012

Yi-Jing Fan , Hui-Qian Xu , Hong Li , Zi-rui Zhang , Shu-Fang Zhang , Ai-Jun Du , Li-zhi Zhou , Yang Wang

Background

Breast cancer-related lymphedema (BCRL) is a relatively common and harmful complication after breast cancer surgery, and there is currently no effective cure. We hypothesized that, compared with the control group, 12 weeks of resistance exercise at different intensities could reduce the incidence of BCRL after axillary lymph node dissection.

Methods

114 breast cancer patients undergoing axillary lymph node dissection were randomly divided into a Control Group (CG), a Low-to-Moderate Intensity Exercise Group (L-MIEG, 40%-70% 1-RM) and a Moderate-to-High Intensity Exercise Group (M-HIEG, 60%-85% 1-RM).

Results

(1) The 12-month cumulative BCRL incidence was higher in the CG (16.3%, 6/37) than in the L-MIEG (8.3%, 3/36) and M-HIEG (5.5%, 2/37). (2) Postintervention and at 6-and 12- month follow-ups, both intervention groups had smaller interlimb differences than the CG (P < .05), and the M-HIEG had smaller differences at 6-month than the L-MIEG (P < .05). (3) InBody analysis showed both intervention groups outperformed CG in segmental water differences, extracellular water (ECW), and single-frequency bioelectrical impedance analysis (SFBIA) (P < .05), and the M-HIEG was better at 6-month (P < .05). (4) At 6-and 12-month follow-ups, both intervention groups improved grip strength more than CG (P < .05), and the M-HIEG was superior at 12 months (P < .05).

Conclusions

Different- intensity resistance exercises benefit BCRL prevention, with M-HIEG being more effective.

背景：乳腺癌相关淋巴水肿（Breast cancer-related lymphodema， BCRL）是乳腺癌手术后较为常见和有害的并发症，目前尚无有效的治疗方法。我们假设，与对照组相比，12周不同强度的阻力运动可以降低腋窝淋巴结清扫后BCRL的发生率。方法：114例行腋窝淋巴结清扫术的乳腺癌患者随机分为对照组（CG）、中低强度运动组（L-MIEG, 40% ~ 70% 1-RM）和中高强度运动组（M-HIEG, 60% ~ 85% 1-RM）。结果：(1)CG组12个月累积BCRL发生率（16.3%,6/37）高于L-MIEG组（8.3%,3/36）和M-HIEG组（5.5%,2/37）。(2)干预后及随访6、12个月时，两组患者肢间差异均小于对照组（P < 0.05），且6个月时M-HIEG差异小于L-MIEG （P < 0.05）。(3) InBody分析显示，两组在节段水差、细胞外水（ECW）和单频生物电阻抗分析（SFBIA）方面均优于CG (P < 0.05)，且M-HIEG在6个月时优于CG （P < 0.05）。(4)随访6个月和12个月时，两组握力的改善均优于对照组（P < 0.05）， 12个月时M-HIEG更优于对照组（P < 0.05）。结论：不同强度的阻力运动有利于预防BCRL，其中M-HIEG更有效。

{"title":"Effects of Resistance Training at Different Intensities on Preventing Breast Cancer-Related Lymphedema: A 1-Year Randomized Controlled Trial","authors":"Yi-Jing Fan , Hui-Qian Xu , Hong Li , Zi-rui Zhang , Shu-Fang Zhang , Ai-Jun Du , Li-zhi Zhou , Yang Wang","doi":"10.1016/j.clbc.2025.07.012","DOIUrl":"10.1016/j.clbc.2025.07.012","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer-related lymphedema (BCRL) is a relatively common and harmful complication after breast cancer surgery, and there is currently no effective cure. We hypothesized that, compared with the control group, 12 weeks of resistance exercise at different intensities could reduce the incidence of BCRL after axillary lymph node dissection.</div></div><div><h3>Methods</h3><div>114 breast cancer patients undergoing axillary lymph node dissection were randomly divided into a Control Group (CG), a Low-to-Moderate Intensity Exercise Group (L-MIEG, 40%-70% 1-RM) and a Moderate-to-High Intensity Exercise Group (M-HIEG, 60%-85% 1-RM).</div></div><div><h3>Results</h3><div>(1) The 12-month cumulative BCRL incidence was higher in the CG (16.3%, 6/37) than in the L-MIEG (8.3%, 3/36) and M-HIEG (5.5%, 2/37). (2) Postintervention and at 6-and 12- month follow-ups, both intervention groups had smaller interlimb differences than the CG (<em>P</em> < .05), and the M-HIEG had smaller differences at 6-month than the L-MIEG (<em>P</em> < .05). (3) InBody analysis showed both intervention groups outperformed CG in segmental water differences, extracellular water (ECW), and single-frequency bioelectrical impedance analysis (SFBIA) (<em>P</em> < .05), and the M-HIEG was better at 6-month (<em>P</em> < .05). (4) At 6-and 12-month follow-ups, both intervention groups improved grip strength more than CG (<em>P</em> < .05), and the M-HIEG was superior at 12 months (<em>P</em> < .05).</div></div><div><h3>Conclusions</h3><div>Different- intensity resistance exercises benefit BCRL prevention, with M-HIEG being more effective.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 204-212"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling SPON2通过调节β-catenin信号传导，在hr阳性/ her2阴性乳腺癌中作为肿瘤启动子。

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-01 DOI: 10.1016/j.clbc.2025.07.030

Gu-yue Liu, Dong-ping Huang, Can Ge, Xiao-yu Li, Fei Chen, Jia-shu Fan, Huan-ping Tu

Background

Spondin-2 (SPON2) expression is associated with various types of cancer, but its role in breast cancer (BC) remains ambiguous, especially in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.

Methods

The expression of SPON2 in HR+/HER2− BC tissues and adjacent tissues was detected using immunohistochemical staining and western blotting. Cell proliferation and migration were assessed via CCK-8 assay, EdU assay, and transwell assay. Animal studies were performed to assess the effect of SPON2 knockdown on tumor growth.

Results

Herein, increased expression of SPON2 was found in HR+/HER2− BC, and silencing SPON2 suppressed cell proliferation, clonogenicity, and migration, whereas SPON2 overexpression had the opposite effects. Notably, SPON2 knockdown significantly suppressed tumor growth in a xenograft tumor assay. Mechanistically, a reduction in SPON2 expression inhibited β-catenin activation, whereas its overexpression promoted β-catenin-mediated proliferation and migration.

Conclusion

These data indicate that SPON2 plays oncogenic roles in HR+/HER2− BC via activating the β-catenin pathway, and may represent a potential therapeutic target for patients diagnosed with HR+/HER2- BC.

背景：Spondin-2 （SPON2）的表达与多种类型的癌症有关，但其在乳腺癌（BC）中的作用尚不清楚，特别是在激素受体阳性(HR+)/人表皮生长因子受体2阴性（HER2-） BC中。方法：采用免疫组化染色和western blotting检测SPON2在HR+/HER2- BC组织及癌旁组织中的表达。通过CCK-8法、EdU法和transwell法检测细胞增殖和迁移。通过动物实验来评估SPON2敲低对肿瘤生长的影响。结果：在HR+/HER2- BC中发现SPON2表达增加，沉默SPON2可抑制细胞增殖、克隆性和迁移，而过表达SPON2则具有相反的作用。值得注意的是，在异种移植肿瘤实验中，SPON2敲低显著抑制肿瘤生长。从机制上讲，SPON2表达的减少抑制了β-catenin的激活，而其过表达促进了β-catenin介导的增殖和迁移。结论：这些数据表明，SPON2通过激活β-catenin通路在HR+/HER2- BC中发挥致癌作用，可能是HR+/HER2- BC患者的潜在治疗靶点。

{"title":"SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling","authors":"Gu-yue Liu, Dong-ping Huang, Can Ge, Xiao-yu Li, Fei Chen, Jia-shu Fan, Huan-ping Tu","doi":"10.1016/j.clbc.2025.07.030","DOIUrl":"10.1016/j.clbc.2025.07.030","url":null,"abstract":"<div><h3>Background</h3><div>Spondin-2 (SPON2) expression is associated with various types of cancer, but its role in breast cancer (BC) remains ambiguous, especially in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.</div></div><div><h3>Methods</h3><div>The expression of SPON2 in HR+/HER2− BC tissues and adjacent tissues was detected using immunohistochemical staining and western blotting. Cell proliferation and migration were assessed via CCK-8 assay, EdU assay, and transwell assay. Animal studies were performed to assess the effect of SPON2 knockdown on tumor growth.</div></div><div><h3>Results</h3><div>Herein, increased expression of SPON2 was found in HR+/HER2− BC, and silencing SPON2 suppressed cell proliferation, clonogenicity, and migration, whereas SPON2 overexpression had the opposite effects. Notably, SPON2 knockdown significantly suppressed tumor growth in a xenograft tumor assay. Mechanistically, a reduction in SPON2 expression inhibited β-catenin activation, whereas its overexpression promoted β-catenin-mediated proliferation and migration.</div></div><div><h3>Conclusion</h3><div>These data indicate that SPON2 plays oncogenic roles in HR+/HER2− BC via activating the β-catenin pathway, and may represent a potential therapeutic target for patients diagnosed with HR+/HER2- BC.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 298-305"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain 在患有乳腺癌和疼痛的妇女中，检查淋巴水肿与疼痛、身体功能、人口统计学和医学变量的相互关系。

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-01 DOI: 10.1016/j.clbc.2025.07.008

Grace H. Amaden , Kelly A. Hyland , Joseph G. Winger , Sarah A. Kelleher , Allison K. Diachina , Shannon N. Miller , Kelly Westbrook , Gretchen Kimmick , Linda Sutton , Mei R. Fu , Tamara J. Somers

Purpose

To examine the relationship of lymphedema with pain, physical function, and demographic and medical variables in women with breast cancer and pain.

Methods

Secondary analysis of baseline data from a study of women with breast cancer and pain. Self-report questionnaires assessed lymphedema, pain severity, pain medication use behavior, pain-related cognitions (ie, pain self-efficacy, pain catastrophizing), and physical function (ie, basic and intermediate activities of daily living (ADLs)). Demographic and medical variables were extracted from the medical record. Univariate analyses examined relationships among lymphedema and variables of interest.

Results

Women (N = 327, M_age = 57 years, 63% White) reported moderate pain severity (M = 4.04). Twenty-six percent of women (n = 85) reported having lymphedema. Women with lymphedema endorsed greater pain severity (P = .007) and pain catastrophizing (P = .015) than women without lymphedema; groups did not differ on pain medication use or pain self-efficacy. Women with lymphedema reported a reduced capacity to complete intermediate ADLs compared to women without lymphedema (P = .044); groups did not differ on ability to complete basic ADLs. Women with lymphedema were more likely to be non-White, have lower educational attainment, have undergone lymph node removal or dissection, and received radiation therapy.

Conclusion

In women with breast cancer and moderate pain, lymphedema is associated with greater pain severity and pain catastrophizing, and decreased ability to complete intermediate ADLs. Women with lymphedema and pain may benefit from tailored, accessible cognitive-behavioral-physiological interventions to improve self-management (eg, Pain Coping Skills Training, interventions to promote lymph flow and reduce inflammation). Disparities in lymphedema prevalence by race and education warrant further exploration.

目的：探讨患有乳腺癌和疼痛的妇女的淋巴水肿与疼痛、身体功能、人口统计学和医学变量的关系。方法：对一项乳腺癌和疼痛妇女研究的基线数据进行二次分析。自我报告问卷评估了淋巴水肿、疼痛严重程度、止痛药使用行为、疼痛相关认知（即疼痛自我效能、疼痛灾难化）和身体功能（即日常生活的基本和中间活动（ADLs））。从病历中提取人口统计学和医学变量。单变量分析检验了淋巴水肿和相关变量之间的关系。结果：女性（N = 347，年龄57岁，63%白人）报告中度疼痛严重程度（M = 4.04）。26%的女性（n = 85）报告有淋巴水肿。与没有淋巴水肿的女性相比，有淋巴水肿的女性有更严重的疼痛（P = .007）和更严重的疼痛（P = .015）；各组在止痛药使用和疼痛自我效能上没有差异。与没有淋巴水肿的女性相比，有淋巴水肿的女性完成中期adl的能力降低（P = 0.044）；各组完成基本adl的能力无差异。患有淋巴水肿的女性更多是非白人，受教育程度较低，接受过淋巴结切除或清扫，并接受过放射治疗。结论：在患有乳腺癌和中度疼痛的女性中，淋巴水肿与更严重的疼痛和疼痛灾难化以及完成中期adl的能力下降有关。患有淋巴水肿和疼痛的妇女可能受益于量身定制的、可获得的认知-行为-生理干预措施，以改善自我管理（例如，疼痛应对技能培训，促进淋巴流动和减少炎症的干预措施）。淋巴水肿患病率的种族和教育差异值得进一步探讨。

{"title":"Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain","authors":"Grace H. Amaden , Kelly A. Hyland , Joseph G. Winger , Sarah A. Kelleher , Allison K. Diachina , Shannon N. Miller , Kelly Westbrook , Gretchen Kimmick , Linda Sutton , Mei R. Fu , Tamara J. Somers","doi":"10.1016/j.clbc.2025.07.008","DOIUrl":"10.1016/j.clbc.2025.07.008","url":null,"abstract":"<div><h3>Purpose</h3><div>To examine the relationship of lymphedema with pain, physical function, and demographic and medical variables in women with breast cancer and pain.</div></div><div><h3>Methods</h3><div>Secondary analysis of baseline data from a study of women with breast cancer and pain. Self-report questionnaires assessed lymphedema, pain severity, pain medication use behavior, pain-related cognitions (ie, pain self-efficacy, pain catastrophizing), and physical function (ie, basic and intermediate activities of daily living (ADLs)). Demographic and medical variables were extracted from the medical record. Univariate analyses examined relationships among lymphedema and variables of interest.</div></div><div><h3>Results</h3><div>Women (<em>N</em> = 327, M<sub>age</sub> = 57 years, 63% White) reported moderate pain severity (<em>M</em> = 4.04). Twenty-six percent of women (<em>n</em> = 85) reported having lymphedema. Women with lymphedema endorsed greater pain severity (<em>P</em> = .007) and pain catastrophizing (<em>P</em> = .015) than women without lymphedema; groups did not differ on pain medication use or pain self-efficacy. Women with lymphedema reported a reduced capacity to complete intermediate ADLs compared to women without lymphedema (<em>P</em> = .044); groups did not differ on ability to complete basic ADLs. Women with lymphedema were more likely to be non-White, have lower educational attainment, have undergone lymph node removal or dissection, and received radiation therapy.</div></div><div><h3>Conclusion</h3><div>In women with breast cancer and moderate pain, lymphedema is associated with greater pain severity and pain catastrophizing, and decreased ability to complete intermediate ADLs. Women with lymphedema and pain may benefit from tailored, accessible cognitive-behavioral-physiological interventions to improve self-management (eg, Pain Coping Skills Training, interventions to promote lymph flow and reduce inflammation). Disparities in lymphedema prevalence by race and education warrant further exploration.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 179-186"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Imaging Biomarkers to Improve Equity in Supplemental and High-Risk Breast Cancer Screening Between Black and White Women: A Perspective on Background Parenchymal Enhancement and Breast Density 探索成像生物标志物以提高黑人和白人女性补充和高危乳腺癌筛查的公平性：从背景实质增强和乳腺密度的角度

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical breast cancer

Pub Date : 2026-01-01 DOI: 10.1016/j.clbc.2025.07.009

Mattia A. Mahmoud , Oluwadamilola M. Fayanju , Anne Marie McCarthy , Carla R. Zeballos Torrez , Christine E. Edmonds

Purpose

Breast density is recognized as a well-established risk factor for breast cancer, influencing screening recommendations. While quantitative measures of breast density have been developed to address limitations of qualitative measures, the role of racial differences in quantitative measures and their effect on breast cancer risk, especially in Black women, remains unclear. Additionally, while background parenchymal enhancement (BPE) is an established as a predictor of breast cancer risk, no research has been conducted to investigate whether the impact of BPE varies by race or ethnicity. This perspective reviews existing data on BPE, specifically its relationship with breast density and breast cancer risk and emphasizes the need for further investigation in Black women.

Discussion

Current supplemental screening methods are heavily reliant on qualitative breast density assessments, which may disadvantage Black women. Although BPE has been significantly associated with breast cancer risk independent of breast density, no studies were found that explored the relationship between BPE and breast cancer risk in Black women.

Conclusion

The limited data on absolute quantitative density measures, such as dense volume, which could improve screening practices, is highlighted in this review. While BPE is well-established as a breast cancer risk factor, further research is needed to investigate racial differences in BPE and its association with breast cancer risk, particularly among Black women.

目的：乳腺密度被认为是乳腺癌的一个确定的危险因素，影响筛查建议。虽然已经开发了乳腺密度的定量测量来解决定性测量的局限性，但种族差异在定量测量中的作用及其对乳腺癌风险的影响，特别是在黑人妇女中，仍然不清楚。此外，虽然背景实质增强（BPE）已被确定为乳腺癌风险的预测因子，但没有研究调查BPE的影响是否因种族或民族而异。本观点回顾了BPE的现有数据，特别是其与乳腺密度和乳腺癌风险的关系，并强调需要对黑人妇女进行进一步调查。讨论：目前的补充筛查方法严重依赖于定性乳腺密度评估，这可能对黑人妇女不利。尽管与乳腺密度无关的BPE与乳腺癌风险显著相关，但没有研究发现BPE与黑人女性乳腺癌风险之间的关系。结论：本综述强调了绝对定量密度测量（如密度体积）的有限数据，这些数据可以改善筛查方法。虽然BPE已被确定为乳腺癌的危险因素，但需要进一步研究BPE的种族差异及其与乳腺癌风险的关系，特别是在黑人妇女中。

{"title":"Exploring Imaging Biomarkers to Improve Equity in Supplemental and High-Risk Breast Cancer Screening Between Black and White Women: A Perspective on Background Parenchymal Enhancement and Breast Density","authors":"Mattia A. Mahmoud , Oluwadamilola M. Fayanju , Anne Marie McCarthy , Carla R. Zeballos Torrez , Christine E. Edmonds","doi":"10.1016/j.clbc.2025.07.009","DOIUrl":"10.1016/j.clbc.2025.07.009","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast density is recognized as a well-established risk factor for breast cancer, influencing screening recommendations. While quantitative measures of breast density have been developed to address limitations of qualitative measures, the role of racial differences in quantitative measures and their effect on breast cancer risk, especially in Black women, remains unclear. Additionally, while background parenchymal enhancement (BPE) is an established as a predictor of breast cancer risk, no research has been conducted to investigate whether the impact of BPE varies by race or ethnicity. This perspective reviews existing data on BPE, specifically its relationship with breast density and breast cancer risk and emphasizes the need for further investigation in Black women.</div></div><div><h3>Discussion</h3><div>Current supplemental screening methods are heavily reliant on qualitative breast density assessments, which may disadvantage Black women. Although BPE has been significantly associated with breast cancer risk independent of breast density, no studies were found that explored the relationship between BPE and breast cancer risk in Black women.</div></div><div><h3>Conclusion</h3><div>The limited data on absolute quantitative density measures, such as dense volume, which could improve screening practices, is highlighted in this review. While BPE is well-established as a breast cancer risk factor, further research is needed to investigate racial differences in BPE and its association with breast cancer risk, particularly among Black women.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 187-194"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0